Pharmafile Logo

Xospata

- PMLiVE

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

- PMLiVE

NICE appraisal fees to be introduced despite opposition

Concessions made for small companies

- PMLiVE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

But it is only available via the CDF for now

- PMLiVE

Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year's tally

- PMLiVE

Astellas makes another gene therapy play with Juventas deal

Targeting faecal incontinence, which affects 50m worldwide

- PMLiVE

Medical cannabis now available on prescription, for some

But it can’t be prescribed for chronic pain

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links